{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:10:39Z","timestamp":1789031439356,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00174-x","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:53:48Z","timestamp":1789030428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab monotherapy for relapsed AL amyloidosis: a single center retrospective analysis"],"prefix":"10.1007","volume":"61","author":[{"given":"Jun Ho","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-oh","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junseok","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"1","key":"174_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"174_CR2","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","volume":"32","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32(10):920\u20138.","journal-title":"Adv Ther"},{"issue":"1","key":"174_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46\u201358.","journal-title":"N Engl J Med"},{"issue":"4","key":"174_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaccao.2022.08.011","volume":"4","author":"MC Minnema","year":"2022","unstructured":"Minnema MC, Dispenzieri A, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, et al. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial. JACC CardioOncology. 2022;4(4):474\u201387.","journal-title":"JACC CardioOncology"},{"issue":"18","key":"174_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood.2019004369","volume":"135","author":"M Roussel","year":"2020","unstructured":"Roussel M, Merlini G, Chevret S, Arnulf B, Stoppa AM, Perrot A, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531\u201340.","journal-title":"Blood"},{"issue":"18","key":"174_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood.2019004436","volume":"135","author":"V Sanchorawala","year":"2020","unstructured":"Sanchorawala V, Sarosiek S, Schulman A, Mistark M, Migre ME, Cruz R, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541\u20137.","journal-title":"Blood"},{"issue":"2","key":"174_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","volume":"33","author":"JP Abeykoon","year":"2019","unstructured":"Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019;33(2):531\u20136.","journal-title":"Leukemia"},{"issue":"2","key":"174_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/ejh.13535","volume":"106","author":"T Shragai","year":"2021","unstructured":"Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, et al. Daratumumab for relapsed AL amyloidosis-when cumulative real-world data precedes clinical trials: a multisite study and systematic literature review. Eur J Haematol. 2021;106(2):184\u201395.","journal-title":"Eur J Haematol"},{"issue":"1","key":"174_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2442075","volume":"57","author":"Z Li","year":"2025","unstructured":"Li Z, Guo J, Chen W, Zhao L, Ren G, Huang X. Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis. Ann Med. 2025;57(1):2442075.","journal-title":"Ann Med"},{"issue":"3","key":"174_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13506129.2020.1730791","volume":"27","author":"R Lecumberri","year":"2020","unstructured":"Lecumberri R, Krsnik I, Askari E, Sirvent M, Gonz\u00e1lez-P\u00e9rez MS, Escalante F, et al. Treatment with daratumumab in patients with relapsed\/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. Amyloid. 2020;27(3):163\u20137.","journal-title":"Amyloid"},{"issue":"9","key":"174_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395.","journal-title":"J Clin Oncol"},{"issue":"5","key":"174_CR12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612\u20135.","journal-title":"Blood"},{"issue":"15","key":"174_CR13","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325\u201332.","journal-title":"Blood"},{"issue":"11","key":"174_CR14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317\u201325.","journal-title":"Leukemia"},{"issue":"7","key":"174_CR15","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/JCO.22.00643","volume":"41","author":"E Muchtar","year":"2023","unstructured":"Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, et al. Graded cardiac response criteria for patients with systemic light chain amyloidosis. J Clin Oncol. 2023;41(7):1393\u2013403.","journal-title":"J Clin Oncol"},{"issue":"14","key":"174_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood.2022019406","volume":"142","author":"MA Gertz","year":"2023","unstructured":"Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, et al. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. 2023;142(14):1208\u201318.","journal-title":"Blood"},{"key":"174_CR17","unstructured":"Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis 2025. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/update-on-anselamimab-in-al-amyloidosis.html."},{"issue":"3","key":"174_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/ndt\/gfq482","volume":"26","author":"R Specter","year":"2011","unstructured":"Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transpl. 2011;26(3):881\u20136.","journal-title":"Nephrol Dial Transpl"},{"issue":"23","key":"174_CR19","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1182\/blood-2010-09-305136","volume":"116","author":"U Tapan","year":"2010","unstructured":"Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A, Zeldis JB, et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood. 2010;116(23):5071\u20132.","journal-title":"Blood"},{"issue":"21","key":"174_CR20","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1182\/blood.V124.21.4741.4741","volume":"124","author":"AD Cohen","year":"2014","unstructured":"Cohen AD, Scott EC, Liedtke M, Kaufman JL, Landau H, Vesole DH, et al. A phase I dose-escalation study of carfilzomib in patients with previously-treated systemic light-chain (AL) amyloidosis. Blood. 2014;124(21):4741.","journal-title":"Blood"},{"issue":"1","key":"174_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","volume":"30","author":"AD Wechalekar","year":"2023","unstructured":"Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023;30(1):3\u201317.","journal-title":"Amyloid"},{"issue":"1","key":"174_CR22","first-page":"67","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr., Baljevic M, Campagnaro E, et al. Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(1):67\u201381.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Supplement 1","key":"174_CR23","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.1182\/blood-2022-158270","volume":"140","author":"A Girvan","year":"2022","unstructured":"Girvan A, Yu J, Emechebe N, Kamalakar R, Luo Y. Real-world treatment patterns and outcomes of daratumumab retreatment in multiple myeloma in the United States. Blood. 2022;140(Supplement 1):5266\u20137.","journal-title":"Blood"},{"issue":"16_suppl","key":"174_CR24","doi-asserted-by":"publisher","first-page":"7570","DOI":"10.1200\/JCO.2024.42.16_suppl.7570","volume":"42","author":"CRC Tan","year":"2024","unstructured":"Tan CRC, Rueda C, Shekarkhand T, Derkach A, Korde N, Maclachlan K, et al. Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma. J Clin Oncol. 2024;42(16_suppl):7570.","journal-title":"J Clin Oncol"},{"key":"174_CR25","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2023-191133","volume":"142","author":"C Rosenbaum","year":"2023","unstructured":"Rosenbaum C, Liedtke M, Christos P, Kim H, Pogonowski K, Agudo N, et al. Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed\/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab. Blood. 2023;142:3402.","journal-title":"Blood"},{"issue":"17","key":"174_CR26","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO-24-02252","volume":"43","author":"E Lebel","year":"2025","unstructured":"Lebel E, Asherie N, Kfir-Erenfeld S, Grisariu S, Avni B, Elias S, et al. Efficacy and safety of anti-B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis. J Clin Oncol. 2025;43(17):2007\u201316.","journal-title":"J Clin Oncol"},{"issue":"3","key":"174_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/ejh.14348","volume":"114","author":"M Stalker","year":"2025","unstructured":"Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, et al. Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis. Eur J Haematol. 2025;114(3):443\u20137.","journal-title":"Eur J Haematol"},{"issue":"3","key":"174_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/13506129.2022.2164488","volume":"30","author":"S Kumar","year":"2023","unstructured":"Kumar S, Dispenzieri A, Bhutani D, Gertz M, Wechalekar A, Palladini G, et al. Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. Amyloid. 2023;30(3):268\u201378.","journal-title":"Amyloid"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00174-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00174-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00174-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:53:50Z","timestamp":1789030430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00174-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00174-x","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"52"}}